Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
|Articles|January 1, 1998
The American Journal of Managed Care
- January 1998
- Volume 4
- Issue 1
Economic Benefits of Aggressive Lipid Lowering: A Managed Care Perspective
Author(s)James M. McKenney, PharmD, Bruce Kinosian, MD
Advertisement
Articles in this issue
almost 29 years ago
Management of Asymptomatic Carotid Bruitalmost 29 years ago
Electroconvulsive Therapy and Managed Carealmost 29 years ago
Parenteral and Enteral Nutrition in Acute Care Settingsalmost 29 years ago
Correspondence regarding, Abstract SectionAdvertisement
Related to this article
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Preparing Practices for the Next Era of Hepatitis B Care
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5